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Since 2000, radiofrequency (RF) energy treatment has been increasingly oﬀered as an alternative option to invasive surgical
procedures for selected patients with gastroesophageal reﬂux disease (GERD). Out of 69 patients treated since June 2002 to
December 2007with theStrettaprocedure, 56ofthem reached bytheend of2010 a48-monthfollowup. RFtreatment signiﬁcantly
improved heartburn scores, GERD-speciﬁc quality of life scores, and general quality of life scores at 24 and 48 months in 52 out of
56patients(92,8%).AteachcontroltimebothmeanheartburnandGERDHRQLscoresdecreased(P =0.001andP =0.003,resp.)
andbothmentalSF-36andph ysicalSF-36ameliorated(P =0.001and0.05,resp.).At48months,41outof56patients(72,3%)were
completely oﬀ PPIs. Morbidity was minimal, with only one relevant but transient complication. According to other literature data,
this study shows that RF delivery to LES is safe and durably improves symptoms and quality of life in well-selected GERD patients.
1.Introduction
GERD is a chronic condition involving spontaneous and
involuntary reﬂux of stomach contents into the oesophagus
most frequently caused by the incompetence of the lower
oesophageal sphincter (LES).
The prevalence of GERD in western countries ranges
between 10 and 20 per cent [1]; treatment depends upon
symptom severity and individual patient characteristics and
often requires long-term medical therapy or laparoscopic
surgery [2]. Despite that, about 20% of patients will have
breakthrough heartburn and regurgitation and long-term
use of medications, which provides a signiﬁcant and life-
lasting economic expense.
Since the main goal of treating GERD would be the
achievement by the patient of a sustained better quality
of life and neither medical nor surgical therapy meet the
idealized criteria of being simple, eﬀective, risk-free and
nonexpensive, a wide number of endoscopic procedures
to create an antireﬂux eﬀective barrier, thus obviating the
cost of long-term PPIs treatment and potential risks of
laparoscopic surgery, have been recently described [3, 4].
In April 2000, the FDA approved the Stretta system
(CuronMedical,FremontCA,USA)foruseasanendoscopic
treatment for patients with GERD [5] that was increasingly
oﬀered as ﬁrst-line therapy before more invasive surgical
procedures for selected GERD patients, with clinical data
supporting its eﬃcacy,safety,andpatient satisfaction[6–10].
The device imparts RF ablation to the dysfunctional
lower oesophageal sphincter via the endoscopic balloon-
mounted needles. Energy is applied at six to eight levels cir-
cumferentially around the oesophageal junction. Two main
goals are achieved: ﬁrst, scarring of the distal oesophageal
muscular wall improves the reﬂux barrier of the lower
oesophageal sphincter; second, reduced transient lower
oesophageal sphincter relaxations occur due to ablation or
demodulation of vagal aﬀerent ﬁbres in the vicinity.
This prospective study reports our experience using the
Stretta procedure in strictly selected patients suﬀering of
GERD who have been followed up for 4 years.2 Diagnostic and Therapeutic Endoscopy
2.MaterialsandMethods
From June 2002 to December 2007, we have selected and
treated a total of 69 patients with the Stretta procedure and
56 of them reached by the end of 2010 a 48-month followup.
The device was not available on the market from late 2006
through the end of 2010, when the study protocol has been
restarted.
Baseline characteristics of the patients are outlined in
Table 1.
Most patients had breakthrough symptoms while on
pharmacologic treatment or were not willing to take drugs
for a lifetime and/or refused laparoscopic antireﬂux surgery.
Participants met the following criteria: (1) heartburn or
acid regurgitation quite well responsive to daily medication
with proton pump inhibitors (PPIs); (2) age >18 years;
(3) 24-hour pH study (oﬀ medication) showing abnormal
oesophageal acid exposure (≥4%) and a De Meester score of
more than 14.7; (4) oesophageal manometry showing both
normal peristalsis and sphincter relaxation and LES pressure
below 10mmHg and more than 5mmHg; (5) at upper
endoscopy (EGD) on medications, no evidence or low-
grade oesophagitis (Los Angeles grade A-B) [11], no hiatal
hernia or not longer than 2cm, and no Barrett’s oesophagus;
ﬁnally, (6) coagulation disorders, previous oesophagogastric
surgery, relevant cardiovascular, and metabolic diseases,
cancer, psychiatric disorders, or nutritional behaviour dis-
turbs such as anorexia and bulimia were excluded. Patients
showing at manometry signiﬁcant ineﬀective oesophageal
motility (IEM) associated with GERD were also excluded.
Theinstitutionalreviewboardapprovedtheprotocoland
all patients provided written informed consent.
The procedure was performed using the technique ﬁrst
described by Triadaﬁlopoulos [12]; during a deeply sedated
EGD, the operator conﬁrms the eligibility criteria and
measures the position of the squamo-columnar junction
(used as the approximate location for the gastroesophageal
junction); then the endoscope is withdrawn and the RF
deliverycatheterwasintroducedorallyoveraguidewire.The
Stretta catheter consists of an inﬂatable and ﬂexible balloon-
basket with four electrode needle sheaths. The operator
inﬂates the balloon 2cm proximal to the squamo-columnar
junction, deploys the electrode needles (22-gauge, 5.5-mm
length),anddeliversRFenergyfor90seconds;since2005the
RF delivery protocol was changed and a highest RF energy
was subsequently delivered only for 60 seconds. The needles
are then withdrawn, the balloon deﬂated, and the catheter
rotated 45◦. This process is serially repeated every 0.5cm,
covering an area 2cm above and 1.5cm below the squamo-
columnar junction plus six sets below the cardias, for a total
of 22 sets of needle deployments.
A l lp r o c e d u r e sw e r ep e r f o r m e do na no u t p a t i e n td a y -
hospital basis; for deep sedation we employed propofol
(100–300mg i.v.) and remifentanil (0.5–1mg/kg/h i.v.), with
continue cardiorespiratory monitoring by an anesthetist well
trained in assistance to the endoscopic procedures. Recovery
mean time after procedure was 4–6 hours, and all patients
were discharged from the hospital within the day.
Table 1: Baseline characteristics of treated patients (n = 56)a.
Mean age (yr) 42 ±14
Male sex, n (%) 36 (64.2)
Mean heartburn score 3.8 ±1.9
Mean HRQL scoreb 29 ±9
Mean SF-36 mental 40 ±7
Mean SF-36 physicalc 41 ± 7
Daily PPI use, n (%) 56 (100)
Median 24-h pHd 15.85 (5.9–18.2)
Median LES pressure (mmHg) 8.44 (7.2–11.7)
<2cm hiatal hernia, n (%) 28 (50)
Erosive esophagitis at EGD, n (%)e 14 (25)
EGD: esophagogastroduodenoscopy; LES: lower esophageal sphincter.
aMeans report ±1 SD, medians report 25th and 75th percentile ranges, and
proportions report absolute numbers (percentiles).
bHeartburn and heartburn-related quality of life scores (higher scores for
worse symptoms).
cSF-36physicalscore(higherscoresforbetterfunction;U.S.general“healthy
group” population mean = 55.3).
dPercentage of time esophageal pH was <4( o ﬀ antisecretory medications).
eTen patients with grade A and four patients with grade B esophagitis
according to the Los Angeles classiﬁcation.
The median procedure time (from starting the initial
endoscopy to the catheter removal) was 50 minutes (45–
70min). EGD was performed immediately posttreatment
to evaluate the RF-induced lesion placement. All patients
continued their current PPIs regimen for 30 days and
then discontinued all antacid medications. For symptom
recurrence, a standard step-up protocol was used, starting
with antacids followed by H2-receptor antagonists and PPIs
until symptom relief was achieved.
The primary outcomes of the study were heartburn
(using a 6-point Likert scale ranging from no symptoms
to incapacitating symptoms), GERD health-related quality
of life (HRQL), using a 6-point Likert scale for multiple
diﬀerent symptoms, each ranging from no symptoms to
incapacitating symptoms [13], and general quality of life,
using the medical outcomes 36-item Short-Form Health
Survey (SF-36) [14].
GERD HRQL improvement was evaluated as a contin-
uous variable and as a dichotomous variable (responder
versus nonresponder). Complete 24 and 48 months clinical
data were available for all patients. A response was a >50%
improvement compared with baseline values, as previously
described [15].
Secondary outcomes included medication use (using
a questionnaire) and LES pressure at oesophageal manome-
try. Adverse events were evaluated by using patient question-
naires and reported on a dedicated report form.
Forstatisticalanalysis,normalitywasassessedgraphically
and with the Shapiro-Wilkes test. For normally distributed
variables, we reported mean values and performed compar-
isons with unpaired and paired t-tests, as appropriate. For
variables without normal distributions, we reported median
values and performed comparisons with the Mann-Whitney
two-sample statistic or the Wilcoxon-matched pairs signedDiagnostic and Therapeutic Endoscopy 3
Figure 1: Means report 95% conﬁdence intervals, medians report
25thand75thpercentileranges,andproportionsreportpercentiles.
Heartburn score used a 6-point Likert scale: 0, no symptoms; 1,
symptoms noticeable but not bothersome; 2, symptoms noticeable
and bothersome, but not every day; 3, symptoms bothersome
e v e ryd a y ;4 ,s y m p t o m sa ﬀect daily life; 5, symptoms incapacitating
(unable to perform daily activities). For symptom scores, the
statistical tests compared the mean/median diﬀerences in absolute
change from baseline values. Heartburn and heartburn-related
quality of life (HRQL) scores when oﬀ antisecretory medications
(higher scores for worse symptoms). SF-36 physical score (higher
s c o r e sf o rb e t t e rf u n c t i o n ) .
rank test, as appropriate. Analyses of dichotomous data (e.g.,
medication use) used the chi-square statistic.
3. Results
Thirteen patients out of the 69 treated by RF delivery at
December 2007 were excluded from the data analysis: 9
patients did not reach by the end of 2010 the 48-month
follow-up visit, 2 patients were lost at followup, and in
2 patients the Stretta procedure was completely ineﬀective
within 6 weeks from the RF delivery and underwent laparo-
scopic antireﬂux surgery without any technical diﬃculty.
Fifty-six patients reached the 48-month follow-up and
accepted to undergo oesophageal manometry at 24 and 48
months and EGD at 48 months.
RF treatment signiﬁcantly improved heartburn scores,
GERD-speciﬁc quality of life scores, and general quality of
life scores at 24 and 48 months in 52 out of 56 patients
(92,8%). At each control time, both mean heartburn and
GERD HRQL scores decreased (P = 0.001 and P = 0.003,
resp.) and both mental SF-36 and physicalSF-36 ameliorated
(P = 0.001 and 0.05, resp.). (Figure 1). Whereas in our
cohort of patients the median LES pressure was previously
described to increase at 12 months [15, 16], only an overall
not signiﬁcant eﬀect from baseline and posttreatment values
was ﬁnally observed at 24 and 48 months (Figure 2).
We did not ﬁnd any diﬀerence in the long-term clinical
outcome between patients who underwent to RF delivery for
90 seconds and 60 seconds, but these second ones received
a signiﬁcantly lower dose of anesthesia and had a shorter
recovery time.





























Figure 2: Mean Less pressure was evaluated by oesophageal
manometry; median basal pressure was 8.44mmHg (7.2–11.7), at
24 months was 9.5 (7.8–10.2) and at 48 months was 9.1 (6.9–9.2).
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Figure 3: The Stretta procedure reduces signiﬁcantly the use
of antireﬂux medication, at 48 months, 41 out of 56 patients
(72,3%)werecompletelyoﬀPPIs(includingOTC-PPIsandanti-H2
antagonists); some patients (14%) were still using only occasionally
oral antacids, none of them on a weekly basis.
At the endoscopic followup at 48 months, none of the
treated patients showed oesophagitis or a picture of Barrett’s
oesophagus.
At 48 months, 41 out of 56 patients (72,3%) were com-
pletely oﬀ PPIs (including OTC-PPIs and anti-H2 antago-
nists); some patients (14%) were still using only occasionally
oral antacids, none of them on a weekly basis (Figure 3).
There were no post procedure perforations, mucosal lac-
erations, bleeding episodes requiring transfusion, or deaths
(Table 2). Minor complications were temporary postpro-
cedure chest discomfort, requiring only oral analgesics,
mild fever, transient nausea, and vomiting and transient
dysphagia. The only major adverse event was a prolonged
transient gastric paresis in a 52-year-old male patient. The
patient had to be hospitalized for 3 weeks and treated with4 Diagnostic and Therapeutic Endoscopy
Table 2: Negative outcomes of the STRETTA procedure.
n (total n = 56) %
Chest pain 15 26.7
Mild fever (<38◦C) 4 7.1
Transient nausea/vomiting 6 10.7
Transient dysphagia 4 7.1
Prolonged gastroparesisa 11 . 7
Perforation 0 —
Mucosal lacerations 0 —
Bleeding requiring transfusion 0 —
Deaths 0 —
aIn a 52-years-old male patient with IEM and delayed gastric emptying
(complete resolution within 8 weeks).
prokinetics,prostigmine,andenteralnutrition.Theproblem
was completely resolved within approximately 8 weeks.
4. Discussion
This study evaluated multiple outcomes, including symptom
scores, GERD-speciﬁc quality of life, and general measures
of quality of life, in 56 consecutive patients submitted to the
Stretta procedure, with a followup of 48 months and without
dropouts. It also directly evaluated oesophageal sphincter
pressure before and after treatment.
Like all other published studies on the RF treatment
for GERD, the current study excluded patients with large
hiatal hernias, severe grade C-D erosive oesophagitis despite
medical treatment, Barrett oesophagus, or primarily extrae-
sophageal manifestations of GERD (e.g., asthma); such
patients should not be treated outside of especially designed
research protocols.
Human and animal studies suggest that RF energy may
ameliorate GERD reducing the frequency of transient LES
relaxations associated with reﬂux episodes, increasing the
intragastric pressure needed to induce reﬂux and improving
the gastric emptying [17–19]. Another potential mecha-
nism for ameliorating GERD symptoms is the decreased
visceral sensitivity, as suggested by the observation that the
time needed to report symptoms during oesophageal acid
perfusion was signiﬁcantly longer than 6 months after the
Stretta procedure [20]. RF energy delivery may inﬂuence
several of these mechanisms as well as the compliance of the
gastroesophageal junction, increasing the resistance of the
LES to a distending pressure and decreasing the volume of
acidic reﬂuxate while the LES relaxes.
In this study, we found that RF energy delivery to the
gastroesophageal junction signiﬁcantly and durably reduced
GERD symptoms, improved GERD HRQL and general
quality of life, and substantially reduced the use of PPIs. Our
clinicaldatameetwithmostoftheliteratureresultsregarding
long-term followup [10, 21–23].
Limitations of these reports include the use of a single
community practice and a nonrandomized or comparative
nature of the studies, but a single-center study is not by itself
ofminorsigniﬁcance.Assuch,itsustainstheimportancethat
these procedures would be still restricted to study protocols
with well-deﬁned patient selection and to well-experienced
and specially trained endoscopist [24]. At our faculty, all
the RF delivery procedures were performed by the same
physician, trained in another centre before starting himself
and with technical assistance provided by Curon Medical Co
for the ﬁrst 10 procedures in order to obtain a good standard
knowledge of the device and control machine.
The lack of 24 hours pH monitoring as a secondary
endpoint in this study is explained by the evidence in the
short-term follow-up reports that acidic exposure is not
constantlyinﬂuencedbytheRFdeliverytotheLES[9,15,16,
21].Neurolysiswithimpairmentofvisceralsensorypathways
has been extensively debated in the mechanism of action
of RF delivery and may play a role as well as oesophageal
exposure to hydrogen ions or the compliance of the gastro-
oesophageal junction with increased resistance of LES to
a distending pressure [17, 20]. Literature data concerning
the long-term followup seem to exclude that oesophageal
desensitization could be harmful in the natural history of the
RF-treated patient.
In the study of Reymunde and Santiago, the RF proce-
dure performed in 83 consecutive patients with persistent
GERDsymptoms,despitemedicaltherapy,resultedinsignif-
icant improvement of QOL and symptom scores; daily med-
ication usage was reduced from 100% at baseline to 13.6%
at 48 months. Moreover, Noar and Lofti-Emran reported on
109 consecutive patients who have reached a complete 4-year
followup and in which heartburn scores and GERD health-
related quality-of-life questionnaire signiﬁcantly improved
with a high patient satisfaction. Medication use decreased
signiﬁcantly from 100% of patients on twice-daily PPI
therapy at baseline to 75% of patients showing elimination
of medications or only as-needed use of antacids/over-
the-counter PPIs at 48 months. The multicenter Stretta
registry study of 558 patients reported signiﬁcant GERD
symptom control and procedure satisfaction superior to
that achieved with drug therapy. Subgroup analysis found
that this superior eﬀect on symptom control and drug use
persisted more than 1 year and that most patients were oﬀ all
antisecretive drugs at followup.
Moreover, the proﬁle of patients who are candidates for
endoscopic therapy has been elucidated [25]. The estimated
20% of patients who have persistent and inadequately
controlled heartburn and regurgitation despite escalating
doses of PPI make up the largest group of patients treated
with the Stretta procedure thus far. Other patients who are
potential candidates for the procedure include the estimated
2% of patients with GERD who cannot tolerate PPI, those
patients with persistent or recurrent GERD symptoms after
antireﬂux surgery, and those patients who want a minimally
invasive alternative to drug treatment.
The Stretta procedure is easily feasible, as conﬁrmed by
the studies reporting a second procedure in patients previ-
ously treated [22, 26] and possibly might be also indicated
for recurrent reﬂux following antireﬂux surgery, especially in
patients who also fail medical management [27]. Although
a recent cost-eﬀectiveness analysis stated that an approach
of prescribing PPIs appears to be the preferable strategy
for GERD [28], the reported long-term clinical results, withDiagnostic and Therapeutic Endoscopy 5
improved responder and durability rates, might suggest
potentially economic advantages for the Stretta procedure
versus the costs of surgery greater than previously estimated.
At this time, in the long-term follow-up studies, the
Stretta procedure has been proven to be very safe for the
treatment of GERD. Randomized sham-controlled studies
as well as single- and multicenter prospective trials have
been conducted. The complication rate is 1.5%, less than the
publishedcomplicationrateforlaparoscopicfundoplication.
Severe but transient gastric paresis has been yet described
in the literature [8, 15] as a rare complication of the Stretta
procedure, probably due to ablation of vagal terminal ﬁbres
in the gastric fundus during RF energy delivery.
In conclusion, according to literature data, the Stretta
procedure is the most widely documented and implemented
endoscopicprocedureforGERDandourstudyalsoconﬁrms
thatRFenergydeliveryissafeandeﬀective,producesdurable
and signiﬁcant improvement in GERD symptoms and qual-
ity of life, as well as reduces the use of antireﬂux medication,
with negligible morbidity.
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